:strip_icc()/s04.video.glbimg.com/x720/9012551.jpg)
[ad_1]
“I determine that ANVISA, based on Article 6, § 1, of Law 9.882 / 1999, that within 48 (forty-eight) hours, observing the scope of its technical autonomy, pay complementary information to those already offered by the Presidency of the Republic and the Attorney General’s Office, on the criteria used to carry out the studies and experiments related to the aforementioned vaccine, as well as on the stage of approval of this and other Covid-19 vaccines“says the order.
In the decision, Lewandowski affirms that it took into account “the relevant public and collective interest discussed in the present process” and article 196 of the Federal Constitution, which deals with the collective right to health.
On the eve of publication, the Ministry of Health had announced the purchase of 46 million doses of the same product, which is still in the testing phase and, therefore, has not been launched for application to the general public anywhere of the world.
CoronaVac is developed by the Chinese pharmaceutical company Sinovac. The government of São Paulo signed an agreement for the purchase of 46 million doses and the production of the immunizer by the Butantan Institute, which coordinates clinical trials in the country.
